Can in vitro studies aid in the development and use of antiseizure therapies? A report of the ILAE/AES Joint Translational Task Force
Morris G., Avoli M., Bernard C., Connor K., de Curtis M., Dulla CG., Jefferys JGR., Psarropoulou C., Staley KJ., Cunningham MO.
AbstractIn vitro preparations (defined here as cultured cells, brain slices, and isolated whole brains) offer a variety of approaches to modeling various aspects of seizures and epilepsy. Such models are particularly amenable to the application of anti‐seizure compounds, and consequently are a valuable tool to screen the mechanisms of epileptiform activity, mode of action of known anti‐seizure medications (ASMs), and the potential efficacy of putative new anti‐seizure compounds. Despite these applications, all disease models are a simplification of reality and are therefore subject to limitations. In this review, we summarize the main types of in vitro models that can be used in epilepsy research, describing key methodologies as well as notable advantages and disadvantages of each. We argue that a well‐designed battery of in vitro models can form an effective and potentially high‐throughput screening platform to predict the clinical usefulness of ASMs, and that in vitro models are particularly useful for interrogating mechanisms of ASMs. To conclude, we offer several key recommendations that maximize the potential value of in vitro models in ASM screening. This includes the use of multiple in vitro tests that can complement each other, carefully combined with in vivo studies, the use of tissues from chronically epileptic (rather than naïve wild‐type) animals, and the integration of human cell/tissue‐derived preparations.